PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: RH Blake, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Prompt Access to Contract Lyophilization and Sterile Pharmaceutical Manufacturing Offered - LyoTechnica, LLC announced today that it has established relationships with multiple parenteral contract manufacturing firms as a means to help speed the development of its clients’ injectable products
Prompt Access to Contract Lyophilization and Sterile Pharmaceutical Manufacturing Offered

 

NewswireToday - /newswire/ - Cleveland, OH, United States, 2010/08/31 - LyoTechnica, LLC announced today that it has established relationships with multiple parenteral contract manufacturing firms as a means to help speed the development of its clients’ injectable products.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“LyoTechnica supports the activities necessary to file INDs, NDAs or ANDAs,” said Glenn Wickes, Jr., president of LyoTechnica. “With the establishment of our network of parenteral contract manufacturers, we are now able to help our clients by recommending the best fit for their contract manufacturing project, whether it be large or small, requiring lyophilization or not.”

LyoTechnica provides a wide range of contract pharmaceutical development services for liquid or lyophilized aseptic dosage forms, including high potency and cytotoxic products as well as small molecule or biopharmaceutical products. The company can provide fast turnaround for parenteral development projects, and has created a process to develop and complete a typical lyophilization cycle development project in under sixty (60) working days from receipt of client-supplied materials. If sterile stability batches are required, the total project can be completed in under 90 days, according to the company. The company offers development through commercial manufacturing of parenterals at the same site. Lyophilization capacity is up to 19,000 10 ml vials per batch.

LyoTechnica, LLC (lyotechnica.com) also provides regulatory support services, including proven expertise in Electronic Common Technical Development (eCTD) submission services. LyoTechnica’s eCTD affiliate has successfully completed 70 eCTD filings and over 300 Electronic Gateway Submission Filings (ESG).

A complete list of services offered by LyoTechnica, LLC includes process design and development (with container / closure selection, lyophilization development, and lyophilization optimization), global sourcing of APIs, process validation support, design space studies, technology transfer documentation, sourcing of contract parenteral manufacturing, sourcing of qualified contract analytical services, project management, regulatory support services and eCTD submission services.

LyoTechnica, LLC is headquartered at 4747 Beachwood Court, Carlsbad, CA 92008. T: 877-792-3737, F: 760-729-3736, E: info[.]lyotechnica.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: RH Blake, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Prompt Access to Contract Lyophilization and Sterile Pharmaceutical Manufacturing Offered

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Bruce Blake - RHblake.com 
216-595-2400 brb[.]rhblake.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any RH Blake, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From RH Blake, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)